Stemcyte International Ltd.
TTWSE:417817.55
TWD
+0.40
(+2.33%)
ISIN
KYG8477S1084
CUSIP
G8477S108
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Tung Yang Li
- Full Time Employees
- 117
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Taipei Taiwan
- IPO Date
- Apr 30, 2026
- Website
- stemcytebio.com
- Similar Companies
- Business
- Stemcyte International Ltd. is a global clinical-stage biotechnology and regenerative cell therapy company that specializes in the development, manufacture, and commercialization of umbilical cord blood-derived cellular biotherapies, comprehensive stem cell banking, and clinical-grade cellular material supply. The company operates through three primary business segments: Cell Therapy, Cell Banking, and Cellular Materials Supply and Services. Its product and service portfolio comprises REGENECYTE, an allogeneic umbilical cord blood hematopoietic progenitor cell therapy approved by the U.S. Food and Drug Administration (FDA) for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system; clinical-stage cell therapy pipeline candidates including CB201, an umbilical cord blood-derived natural killer (CB-NK) cell platform under development for hematological malignancies, alongside investigational regenerative biotherapies undergoing clinical trials for post-acute sequelae of COVID-19 (Long COVID), acute ischemic stroke, spinal cord injury, and cerebral palsy; cell banking solutions encompassing public and private umbilical cord blood collection, processing, and long-term cryopreservation services accredited by the Foundation for the Accreditation of Cellular Therapy (FACT) and the Association for the Advancement of Blood and Biotherapies (AABB); and cell supply services offering human leukocyte antigen (HLA)-typed cord blood units, research-grade and clinical-grade cellular materials, and clinical trial support for transplant centers, research institutions, and biopharmaceutical developers worldwide. Stemcyte International serves medical transplant centers, academic and clinical research institutions, healthcare providers, and individual family clients across North America, the Asia-Pacific region, and global markets. Founded in 1997, the company maintains corporate and operational facilities in Baldwin Park, California, United States, and New Taipei City, Taiwan, operating through principal subsidiaries including StemCyte, Inc. and StemCyte Taiwan. Recent corporate developments include securing U.S. FDA Biologics License Application (BLA) approval for REGENECYTE, making Stemcyte the first private enterprise to achieve a BLA for an unrelated-donor allogeneic cord blood therapy; receiving U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation and FDA clearance for an Expanded Access program for its umbilical cord blood cell therapy targeting Long COVID; establishing a strategic alliance with Taishin Life to launch an integrated public bank matching protection service linking insurance coverage to cellular therapies; expanding its Asia-Pacific footprint through a strategic memorandum of understanding in Malaysia to deploy regional public inventory protection initiatives; and listing its common shares on the Taiwan Stock Exchange under the ticker symbol 4178.